Community-acquired pneumonia. Diagnosis, treatment approaches

The article presents current data on the prevalence and etiology of community-acquired pneumonia, shows the contribution of each of the possible pathogens to the structure of the disease. The diagnostic criteria for pneumonia are given. The main algorithms for assessing the severity of pneumonia and the prognosis of the disease using different scales: CURB-65 / CRB-65, PORT (PSI), are described. The purpose of the test is to determine the place of treatment: outpatient or in the in-patient department, in the general department or in the intensive care unit. The criteria for IDSA / ATS (American Thoracic Society / American Society of Infectious Diseases), as well as the SMART-COP / SMRCO scale to determine the need for hospitalized patients in the intensive care unit, are reviewed. The Aliberti and PES scales are given, assessing the risk of the presence of resistant pathogens in community-acquired pneumonia. Modern recommendations on the empirical choice of antibacterial drugs depending on individual patient factors are presented: anamnestic indications for treatment with antimicrobials during the preceding three months, hospitalization within six months before the onset of pneumonia, the presence of comorbidities, the severity of the disease, the risk of resistant pathogens. The average therapeutic doses of antibacterial drugs for the treatment of community-acquired pneumonia in patients with normal renal function are indicated. The questions of the optimal duration of treatment of pneumonia depending on the etiology are considered, the criteria of sufficiency of antibacterial therapy are presented. The reasons for the possible ineffectiveness of the empirical antibiotic therapy of community-acquired pneumonia are described. The importance of identifying a particular form of community-acquired pneumonia – severe community-acquired pneumonia is emphasized. Described drugs for the treatment of severe community-acquired pneumonia. The issues of prevention of pneumonia were discussed, its importance in the strategy of reducing mortality according to the World Health Organization was emphasized.

1. GBD 2015 Mortality and Causes of Death Collaborators. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 2016;388(10053):1459–544. DOI: 10.1016/S0140-6736(16)31012-1.

2. Project of Federal guidelines. Vnebolnichnaya pnevmoniya = Community-acquired pneumonia. 2018. (In Russ.)

3. Cillóniz C., Cardozo C., García-Vidal C. Epidemiology, pathophysiology, and microbiology of community-acquired pneumonia. Ann Res Hosp 2018;2:1. DOI: 10.21037/arh.2017.12.03.

4. Chuchalin A. G., Sinopalnikov A. I., Kozlov R. S. et al. Clinical recommendations for the diagnosis, treatment and prevention of severe community-acquired pneumonia in adults. Moscow: M–Vesti, 2014. (In Russ.)

5. Cillóniz C., Ewig S., Polverino E. et al. Microbial aetiology of community-acquired pneumonia and its relation to severity. Thorax 2011;66(4):340–6. DOI: 10.1136/thx.2010.143982.

6. Cillóniz C., Polverino E., Ewig S. et al. Impact of age and comorbidity on cause and outcome in community-acquired pneumonia. Chest 2013;144(3):999–1007. DOI: 10.1378/chest.13–0062.

7. Rachina S. A., Kozlov R. S., Dekhnich N. N. et al. Antibacterial therapy of severe community-acquired pneumonia in adults: a review of recommendations and clinical examples. Arkhiv vnutrennej meditsiny = Archive of internal medicine 2015;(3):63–74. (In Russ.)

8. Aliberti S., Cilloniz C., Chalmers J. D., Zanaboni A. M. Multidrug-resistant pathogens in hospitalised patients coming from the community with pneumonia: a European perspective. Thorax 2013;68(11):997–9. DOI: 10.1136/thoraxjnl-2013-203384.

9. Aliberti S., Di Pasquale M., Zanaboni A. M. et al. Stratifying risk factors for multidrug-resistant pathogens in hospitalized patients coming from the community with pneumonia. Clin Infect Dis 2012;54(4):470–8.

10. Prina E., Ranzani O. T., Polverino Е. Risk factors assoсiated with potentially antibiotic resistant pathogens in community-acquired pneumonia. Ann Am Thorac Soc 2015;12(2):153–60.

11. McNally M., Curtain J., O’Brien K. K. Validity of British Thoracic Society guidance (the CRB-65 rule) for predicting the severity of pneumonia in general practice: systematic review and meta-analysis. Br J Gen Pract 2010;60(579): e423–33. DOI: 10.3399/bjgp10X532422.

12. Barlow G., Nathwani D., Davey P. The CURB65 pneumonia severity score outperforms generic sepsis and early warning scores in predicting mortality in community-acquired pneumonia. Thorax 2007;62(3):253–9. DOI: 10.1136/thx.2006.067371.

13. Aujesky D., Fine M. J. The pneumonia severity index: a decade after the initial derivation and validation. Clin Infect Dis 2008;47(Suppl 3):133–9. DOI: 10.1086/591394.

14. Mandell L. A., Wunderink R. G., Anzueto A. et al. Infectious Diseases Society of America / American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007;44(Suppl 2):27–72. DOI: 10.1086/511159.

15. Salih W., Schembri S., Chalmers J. D. Simplification of the IDSA / ATS criteria for severe CAP using meta-analysis and observational data. Eur Respir J 2014;43(3):842–51. DOI: 10.1183/09031936.00089513.

16. Patrick G. P. Charles, Rory Wolfe, Michael Whitby et al. SMART-COP: A Tool for Predicting the Need for Intensive Respiratory or Vasopressor Support in Community-Acquired Pneumonia. Clin Infect Dis 47(3):375–84. DOI.ORG/10.1086/589754.

17. The SCAT program (Strategy for the Control of Antimicrobial Therapy) in the provision of inpatient medical care: guidelines. Moscow, 2016. (In Russ.)

18. The Sanford Guide To Antimicrobial Therapy 2018.

19. Menendez R., Torres A., Zalacain R. et al. Risk factors of treatment failure in community acquired pneumonia: implications for disease outcome. Thorax 2004;59:960–5.

20. Roson B., Carratala J., Fernandez-Sabe N. et al. Causes and factors associated with early failure in hospitalized patients with community-acquired pneumonia. Arch Intern Med 2004;164(5):502–8. DOI: 10.1001/archinte.164.5.502.

21. World Health Organization(WHO). 10 Facts On Immunization. Available at URL: http://www.who.int/features/factfiles/immunization/facts/en/

22. Streptococcus Pneumoniae. In.: Mandell G., Bennett J., Dolin R. Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases. 7thed. Library of Congress Cataloging-in-Publication Data; p. 2623–42.

23. Ewig S., Birkner N., Strauss R. et al. New perspectives on community-acquired pneumonia in 388,406 patients. Results from a nationwide mandatory performance measurement programme in healthcare quality. Thorax 2009;64(12):1062–9. DOI: 10.1136/thx.2008.109785.